Abstract
Respiratory diseases are a major concern in public health, impacting a large population worldwide. Despite the availability of therapies that alleviate symptoms, selectively addressing the critical points of pathopathways remains a major challenge. Innovative formulations designed for reaching these targets within the airways, enhanced selectivity, and prolonged therapeutic effects offer promising solutions. To provide insights into the specific medical requirements of chronic respiratory diseases, the initial focus of this chapter is directed on lung physiology, emphasizing the significance of lung barriers. Current treatments involving small molecules and the potential of gene therapy are also discussed. Additionally, we will explore targeting approaches, with a particular emphasis on nanoparticles, comparing targeted and non-targeted formulations for pulmonary administration. Finally, the potential of inhaled sphingolipids in the context of respiratory diseases is briefly discussed, highlighting their promising prospects in the field.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- API:
-
Active pharmaceutical ingredient
- CA-IX:
-
Carbonic anhydrase IX
- CF:
-
Cystic fibrosis
- COPD:
-
Chronic obstructive pulmonary disease
- DOTAP:
-
1,2-Dioleoyl-3-trimethylammonium-propane
- DPPC:
-
Dipalmitoyl phosphatidylcholine
- DSPE:
-
1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine
- FA:
-
Folic acid
- FR:
-
Folic acid receptor
- KRAS:
-
Kirsten rat sarcoma
- LNP:
-
Lipid nanoparticle
- MCC:
-
Mucociliary clearance
- MMAD:
-
Mass median aerodynamic diameter
- NHS:
-
N-hydroxysuccinimide
- PCLS:
-
Precision-cut lung slices
- PEG:
-
Polyethylene glycol
- PEI:
-
Polyethyleneimine
- PLGA:
-
Poly(lactic-co-glycolic acid)
- SP:
-
Surfactant protein
- Tf:
-
Human holo-transferrin
- TSLP:
-
Thymic stromal lymphopoietin
- VIPER:
-
Virus-inspired polymer for endosomal release
References
Abed S, Turner R, Serniuck N, Tat V, Naiel S, Hayat A, Mekhael O, Vierhout M, Ask K, Rullo AF (2021) Cell-specific drug targeting in the lung. Biochem Pharmacol 190:114577. https://doi.org/10.1016/j.bcp.2021.114577
Alhajj N, O'Reilly NJ, Cathcart H (2021) Leucine as an excipient in spray dried powder for inhalation. Drug Discov Today 26:2384–2396. https://doi.org/10.1016/j.drudis.2021.04.009
Ambike S, Cheng CC, Feuerherd M, Velkov S, Baldassi D, Afridi SQ, Porras-Gonzalez D, Wei X, Hagen P, Kneidinger N, Stoleriu MG, Grass V, Burgstaller G, Pichlmair A, Merkel OM, Ko C, Michler T (2022) Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread. Nucleic Acids Res 50:333–349. https://doi.org/10.1093/nar/gkab1248
Aoki FY (2015) Antiviral drugs for influenza and other respiratory virus infections, pp 531–545.e5. https://doi.org/10.1016/b978-1-4557-4801-3.00044-8
Baldassi D, Gabold B, Merkel O (2021) Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions. Adv Nanobiomed Res 1. https://doi.org/10.1002/anbr.202000111
Baldassi D, Ambike S, Feuerherd M, Cheng CC, Peeler DJ, Feldmann DP, Porras-Gonzalez DL, Wei X, Keller LA, Kneidinger N, Stoleriu MG, Popp A, Burgstaller G, Pun SH, Michler T, Merkel OM (2022a) Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes. J Control Release 345:661–674. https://doi.org/10.1016/j.jconrel.2022.03.051
Baldassi D, Ngo TMH, Merkel OM (2022b) Optimization of lung surfactant coating of siRNA polyplexes for pulmonary delivery. Pharm Res. https://doi.org/10.1007/s11095-022-03443-3
Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184–190. https://doi.org/10.1067/mai.2001.117880
Caini S, Kroneman M, Wiegers T, El Guerche-Seblain C, Paget J (2018) Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: a systematic literature review. Influenza Other Respi Viruses 12:780–792. https://doi.org/10.1111/irv.12575
Carstens H, Schumacher F, Keitsch S, Kramer M, Kuhn C, Sehl C, Soddemann M, Wilker B, Herrmann D, Swaidan A, Kleuser B, Verhaegh R, Hilken G, Edwards MJ, Dubicanac M, Carpinteiro A, Wissmann A, Becker KA, Kamler M, Gulbins E (2019) Clinical development of sphingosine as anti-bacterial drug: inhalation of sphingosine in mini pigs has no adverse side effects. Cell Physiol Biochem 53:1015–1028. https://doi.org/10.33594/000000194
Chaurasiya B, Zhao YY (2020) Dry powder for pulmonary delivery: a comprehensive review. Pharmaceutics 13. https://doi.org/10.3390/pharmaceutics13010031
Chellappan DK, Prasher P, Saravanan V, Vern Yee VS, Wen Chi WC, Wong JW, Wong JK, Wong JT, Wan W, Chellian J, Molugulu N, Prabu SL, Ibrahim R, Darmarajan T, Candasamy M, Singh PK, Mishra V, Shastri MD, Zacconi FC, Chakraborty A, Mehta M, Gupta PK, Dureja H, Gulati M, Singh SK, Gupta G, Jha NK, George Oliver BG, Dua K (2022) Protein and peptide delivery to lungs by using advanced targeted drug delivery. Chem Biol Interact 351:109706. https://doi.org/10.1016/j.cbi.2021.109706
Conte G, Costabile G, Baldassi D, Rondelli V, Bassi R, Colombo D, Linardos G, Fiscarelli EV, Sorrentino R, Miro A, Quaglia F, Brocca P, d'Angelo I, Merkel OM, Ungaro F (2022) Hybrid lipid/polymer nanoparticles to tackle the cystic fibrosis mucus barrier in siRNA delivery to the lungs: does PEGylation make the difference? ACS Appl Mater Interfaces 14:7565–7578. https://doi.org/10.1021/acsami.1c14975
Deacon J, Abdelghany SM, Quinn DJ, Schmid D, Megaw J, Donnelly RF, Jones DS, Kissenpfennig A, Elborn JS, Gilmore BF, Taggart CC, Scott CJ (2015) Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase). J Control Release 198:55–61. https://doi.org/10.1016/j.jconrel.2014.11.022
EMA (2020) Arikayce liposomal epar medicine overview. https://www.ema.europa.eu/en/documents/overview/arikayce-liposomal-epar-medicine-overview_de.pdf. Accessed 14 Aug 2023
Fernandez M, Javaid F, Chudasama V (2018) Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci 9:790–810. https://doi.org/10.1039/c7sc04004k
Gardner AI, Haq IJ, Simpson AJ, Becker KA, Gallagher J, Saint-Criq V, Verdon B, Mavin E, Trigg A, Gray MA, Koulman A, McDonnell MJ, Fisher AJ, Kramer EL, Clancy JP, Ward C, Schuchman EH, Gulbins E, Brodlie M (2020) Recombinant acid ceramidase reduces inflammation and infection in cystic fibrosis. Am J Respir Crit Care Med 202:1133–1145. https://doi.org/10.1164/rccm.202001-0180OC
Geiser M (2010) Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 23:207–217. https://doi.org/10.1089/jamp.2009.0797
Goerke J (1998) Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1408:79–89. https://doi.org/10.1016/S0925-4439(98)00060-X
Guo Y, Ma Y, Chen X, Li M, Ma X, Cheng G, Xue C, Zuo YY, Sun B (2023) Mucus penetration of surface-engineered nanoparticles in various pH microenvironments. ACS Nano. https://doi.org/10.1021/acsnano.2c11147
Hermanson GT (1996) Bioconjugates techniques. 1 edn. Academic Press
Ibarra-Sanchez LA, Gamez-Mendez A, Martinez-Ruiz M, Najera-Martinez EF, Morales-Flores BA, Melchor-Martinez EM, Sosa-Hernandez JE, Parra-Saldivar R, Iqbal HMN (2022) Nanostructures for drug delivery in respiratory diseases therapeutics: revision of current trends and its comparative analysis. J Drug Deliv Sci Technol 70:103219. https://doi.org/10.1016/j.jddst.2022.103219
Idris A, Davis A, Supramaniam A, Acharya D, Kelly G, Tayyar Y, West N, Zhang P, McMillan CLD, Soemardy C, Ray R, O'Meally D, Scott TA, McMillan NAJ, Morris KV (2021) A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19. Mol Ther 29:2219–2226. https://doi.org/10.1016/j.ymthe.2021.05.004
Kandil R, Baldassi D, Bohlen S, Muller JT, Keul DC, Bargmann T, Dehmel S, Xie Y, Mehta A, Sewald K, Merkel OM (2023) Targeted GATA3 knockdown in activated T cells via pulmonary siRNA delivery as novel therapy for allergic asthma. J Control Release. https://doi.org/10.1016/j.jconrel.2023.01.014
Keil TWM, Baldassi D, Merkel OM (2020) T-cell targeted pulmonary siRNA delivery for the treatment of asthma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12:e1634. https://doi.org/10.1002/wnan.1634
Keil TW, Zimmermann C, Baldassi D, Adams F, Friess W, Mehta A, Merkel OM (2021) Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles. Adv Ther (Weinh) 4. https://doi.org/10.1002/adtp.202100073
Klein DM, Poortinga A, Verhoeven FM, Bonn D, Bonnet S, van Rijn CJM (2021) Degradation of lipid based drug delivery formulations during nebulization. Chem Phys:547. https://doi.org/10.1016/j.chemphys.2021.111192
Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H (2015) Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med 372:1987–1995. https://doi.org/10.1056/NEJMoa1411776
Lin C, Zhang X, Chen H, Bian Z, Zhang G, Riaz MK, Tyagi D, Lin G, Zhang Y, Wang J, Lu A, Yang Z (2018) Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide. Drug Deliv 25:256–266. https://doi.org/10.1080/10717544.2018.1425777
Longest W, Spence B, Hindle M (2019) Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs. J Aerosol Med Pulm Drug Deliv 32:317–339. https://doi.org/10.1089/jamp.2018.1508
Lu L, Duong VT, Shalash AO, Skwarczynski M, Toth I (2021) Chemical conjugation strategies for the development of protein-based subunit nanovaccines. Vaccines (Basel) 9. https://doi.org/10.3390/vaccines9060563
Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3:1377–1397. https://doi.org/10.3390/polym3031377
Mandal D, Mohammed EHM, Lohan S, Mandipoor P, Baradaran D, Tiwari RK, Parang K, Aliabadi HM (2022) Redox-responsive disulfide cyclic peptides: a new strategy for siRNA delivery. Mol Pharm 19:1338–1355. https://doi.org/10.1021/acs.molpharmaceut.1c00879
Mattila JM, Vuorinen T, Heikkinen T (2020) Comparative severity of influenza a and B infections in hospitalized children. Pediatr Infect Dis J 39:489–493. https://doi.org/10.1097/INF.0000000000002610
Mayor A, Thibert B, Huille S, Respaud R, Audat H, Heuze-Vourc'h N (2021) Inhaled antibodies: formulations require specific development to overcome instability due to nebulization. Drug Deliv Transl Res 11:1625–1633. https://doi.org/10.1007/s13346-021-00967-w
Munir M, Jena L, Kett VL, Dunne NJ, McCarthy HO (2022a) Spray drying: inhalable powders for pulmonary gene therapy. Biomater Adv 133:112601. https://doi.org/10.1016/j.msec.2021.112601
Munir M, Kett VL, Dunne NJ, McCarthy HO (2022b) Development of a spray-dried formulation of peptide-DNA nanoparticles into a dry powder for pulmonary delivery using factorial design. Pharm Res 39:1215–1232. https://doi.org/10.1007/s11095-022-03256-4
Nakamura YGO, Olivenstein R, Taha RA, Soussi-Gounni A, Zhang D-H, Ray A, Hamid Q (1999) Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol 103:215–222. https://doi.org/10.1016/s0091-6749(99)70493-8
Parra E, Perez-Gil J (2015) Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films. Chem Phys Lipids 185:153–175. https://doi.org/10.1016/j.chemphyslip.2014.09.002
Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, Murugavelu P, Ahmed S, Samal S, Sharma C, Sinha S, Luthra K, Kumar R (2021) Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol 105:6315–6332. https://doi.org/10.1007/s00253-021-11488-4
Pastorek J, Pastorekova S (2015) Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin Cancer Biol 31:52–64. https://doi.org/10.1016/j.semcancer.2014.08.002
Pinto JT, Faulhammer E, Dieplinger J, Dekner M, Makert C, Nieder M, Paudel A (2021) Progress in spray-drying of protein pharmaceuticals: literature analysis of trends in formulation and process attributes. Drying Technol 39:1415–1446. https://doi.org/10.1080/07373937.2021.1903032
Schäfer-Korting M (2023) Looking to the future – drug delivery and targeting in the prophylaxis and therapy of severe and chronic diseases, Handbook of experimental pharmacology, vol x. Springer Nature
Sel S, Wegmann M, Dicke T, Sel S, Henke W, Yildirim AO, Renz H, Garn H (2008) Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme. J Allergy Clin Immunol 121:910–916 e5. https://doi.org/10.1016/j.jaci.2007.12.1175
Shukla SD, Swaroop Vanka K, Chavelier A, Shastri MD, Tambuwala MM, Bakshi HA, Pabreja K, Mahmood MQ, O’Toole RF (2020) Chronic respiratory diseases: an introduction and need for novel drug delivery approaches. Targeting chronic inflammatory lung diseases using advanced drug delivery systems, pp 1–31
Synowiec A, Szczepański A, Barreto-Duran E, Lie LK, Pyrc K (2021) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systemic infection. Clin Microbiol Rev 34:e00133–e00120. https://doi.org/10.1128/CMR.00133-20
Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, Weller M, Tummler B, Lang F, Grassme H, Doring G, Gulbins E (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14:382–391. https://doi.org/10.1038/nm1748
Thompson JE (2018) Airborne particulate matter: human exposure and health effects. J Occup Environ Med 60:392–423. https://doi.org/10.1097/JOM.0000000000001277
van Rijn CJM, Vlaming KE, Bem RA, Dekker RJ, Poortinga A, Breit T, van Leeuwen S, Ensink WA, van Wijnbergen K, van Hamme JL, Bonn D, Geijtenbeek TBH (2023) Low energy nebulization preserves integrity of SARS-CoV-2 mRNA vaccines for respiratory delivery. Sci Rep 13:8851. https://doi.org/10.1038/s41598-023-35872-4
Wang W, Huang Z, Huang Y, Zhang X, Huang J, Cui Y, Yue X, Ma C, Fu F, Wang W, Wu C, Pan X (2022) Pulmonary delivery nanomedicines towards circumventing physiological barriers: strategies and characterization approaches. Adv Drug Deliv Rev 185:114309. https://doi.org/10.1016/j.addr.2022.114309
WHO (n.d.-a) Global summary estimates. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death. Accessed 11 Feb 2023
WHO (n.d.-b) WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/. Accessed 05 Dec 2023
WHO (n.d.-c) Asthma. https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed 17 Feb 2023
WHO (n.d.-d) Infectious diseases. https://www.who.int/teams/integrated-health-services/clinical-services-and-systems/surgical-care/infectious-diseases. Accessed 17 Feb 2023
WHO (n.d.-e) Influenza seasonal. https://www.who.int/health-topics/influenza-seasonal#tab=tab_1. Accessed 17 Feb 2023
Winkeljann B, Keul DC, Merkel OM (2022) Engineering poly- and micelleplexes for nucleic acid delivery – a reflection on their endosomal escape. J Control Release. https://doi.org/10.1016/j.jconrel.2022.12.008
Wüstneck R, Wüstneck N, Grigoriev DO, Pison U, Miller R (1999) Stress relaxation behaviour of dipalmitoyl phosphatidylcholine monolayers spread on the surface of a pendant drop. Colloids Surf B Biointerfaces 15:275–288. https://doi.org/10.1016/S0927-7765(99)00094-6
Xu Y, Harinck L, Lokras AG, Gerde P, Selg E, Sjoberg CO, Franzyk H, Thakur A, Foged C (2022a) Leucine improves the aerosol performance of dry powder inhaler formulations of siRNA-loaded nanoparticles. Int J Pharm 621:121758. https://doi.org/10.1016/j.ijpharm.2022.121758
Xu Y, Parra-Ortiz E, Wan F, Canadas O, Garcia-Alvarez B, Thakur A, Franzyk H, Perez-Gil J, Malmsten M, Foged C (2022b) Insights into the mechanisms of interaction between inhalable lipid-polymer hybrid nanoparticles and pulmonary surfactant. J Colloid Interface Sci 633:511–525. https://doi.org/10.1016/j.jcis.2022.11.059
Yuan ZQ, Li JZ, Liu Y, Chen WL, Yang SD, Zhang CG, Zhu WJ, Zhou XF, Liu C, Zhang XN (2015) Systemic delivery of micelles loading with paclitaxel using N-succinyl-palmitoyl-chitosan decorated with cRGDyK peptide to inhibit non-small-cell lung cancer. Int J Pharm 492:141–151. https://doi.org/10.1016/j.ijpharm.2015.07.022
Zhang M, Jiang H, Wu L, Lu H, Bera H, Zhao X, Guo X, Liu X, Cun D, Yang M (2022) Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J Control Release 352:422–437. https://doi.org/10.1016/j.jconrel.2022.10.020
Zhao D, Li D, Cheng X, Zou Z, Chen X, He C (2022) Mucoadhesive, antibacterial, and reductive nanogels as a mucolytic agent for efficient nebulized therapy to combat allergic asthma. ACS Nano. https://doi.org/10.1021/acsnano.2c03993
Zhu X, Kong Y, Liu Q, Lu Y, Xing H, Lu X, Yang Y, Xu J, Li N, Zhao D, Chen X, Lu Y (2019) Inhalable dry powder prepared from folic acid-conjugated docetaxel liposomes alters pharmacodynamic and pharmacokinetic properties relevant to lung cancer chemotherapy. Pulm Pharmacol Ther 55:50–61. https://doi.org/10.1016/j.pupt.2019.02.001
Zou P, Stern ST, Sun D (2014) PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery. Pharm Res 31:684–693. https://doi.org/10.1007/s11095-013-1190-5
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Carneiro, S., Müller, J.T., Merkel, O.M. (2024). Targeted Molecular Therapeutics for Pulmonary Diseases: Addressing the Need for Precise Drug Delivery. In: Schäfer-Korting, M., Schubert, U.S. (eds) Drug Delivery and Targeting. Handbook of Experimental Pharmacology, vol 284. Springer, Cham. https://doi.org/10.1007/164_2023_703
Download citation
DOI: https://doi.org/10.1007/164_2023_703
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-52863-7
Online ISBN: 978-3-031-52864-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)